A phase 1b study of mesenchymal stromal cell therapy for idiopathic pulmonary fibrosis

      Idiopathic pulmonary fibrosis (IPF) is a lethal degenerative disease characterised by fibrosis following failed epithelial repair. Mesenchymal stromal cells (MSC), a key component of the stem cell niche in bone marrow and possibly other organs including lung, have been shown to enhance epithelial repair and are effective in preclinical models of pulmonary fibrosis, but may be pro-fibrotic in some circumstances. The aim of this study was to confirm the feasibility and safety, particularly with respect to adverse acute haemodynamic effects and pro-fibrosis, of intravenous MSC therapy in humans with IPF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect